- Pharmaceutical technology supplier MaxCyte said it had entered into a clinical and commercial licensing agreement with private biotechnology company Apeiron Biologics.

Apeiron Biologics would obtain non-exclusive clinical and commercial rights to use MaxCyte's technology for the advancement of APN401, a cell therapy currently in clinical development for various solid tumors.

In return, MaxCyte would receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.

At 8:57am: [LON:MXCT] MaxCyte Inc share price was +0.5p at 201p

Story provided by